Company: PHAT
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034183
Chunk: 259

Company: Phathom Pharmaceuticals, Inc.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 1B
Chunk 259
---
 Net loss per share, basic and diluted
     
    $
    (5.29
    )
     
    $
    (3.93
    )

    Weighted-average shares of common stock outstanding, basic and diluted

    63,176,210

    51,289,092

See accompanying notes

F-5

PHATHOM PHARMACEUTICALS, INC. 

Statements of Stockholders’ Deficit

(in thousands, except share amounts) 

    Common Stock

    Treasury Stock

    AdditionalPaid-in

    Accumulated

    TotalStockholders’

    Shares

    Amount

    Shares

    Capital

    Deficit

    Deficit

    Balance at December 31, 2023

    57,970,044

    $
    5

    19

    $
    855,921

    $
    (928,685
    )
     
    $
    (72,759
    )

    401(k) matching contribution

    383,589

    —

    —

    3,683

    —

    3,683

    Vesting of restricted stock units

    965,681

    —

    —

    —

    —

    —

    Stock-based compensation

    —

    —

    —

    24,047

    —

    24,047

    ESPP shares issued

    375,381

    —

    —

    2,401

    —

    2,401

    Issuance of common stock from exercises of stock options

    127,891

    —

    —

    1,599

    —

    1,599

    Issuance of common stock and pre-funded warrants in connection with the underwritten public offering, net

    8,695,652

    1

    —

    121,774

    —

    121,775

    Net loss

    —

    —

    —

    —

    (334,326
    )

    (334,326
    )

    Balance at December 31, 2024

    68,518,238

    $
    6

    19

    $
    1,009,425

    $
    (1,263,011
    )
     
    $
    (253,580
    )

    Common Stock

    Treasury Stock

    AdditionalPaid-in

    Accumulated

    TotalStockholders’